SSSeyyed-Reza Sadat-Ebrahimi

Seyyed-Reza Sadat-Ebrahimi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Seyyed-Reza Sadat-Ebrahimi has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Akbar Molaei

    Cardiovascular research center, Shahid Madani Heart Center, Tabriz University of Medical Sciences, Tabriz, Iran

    4 shared publications
  • Azizollah Khomahani

    Pediatric Health Research Center, Tabriz Children Hospital, Tabriz University of Medical Sciences, Tabriz, Iran

    3 shared publications
  • Davoud Ezzati

    Department of Psychology, School of Psychology University of Tabriz Tabriz Iran

    3 shared publications
  • Fatemeh Jamshidi

    Cardiovascular Research Center Tabriz University of Medical Sciences Tabriz Iran

    3 shared publications
  • Hossein Namdar

    Cardiovascular Research Center Tabriz University of Medical Sciences Tabriz Iran

    3 shared publications
  • Mahnaz Sadeghi-Shabestari

    Pediatric Health Research Center, Tabriz Children Hospital, Tabriz University of Medical Sciences, Tabriz, Iran

    3 shared publications

Latest Publications

  • Open Access

    Hub Genes and Therapeutic Pathways of CTRP9 in Cardiac Ischemia/Reperfusion Injury: A Bioinformatics Perspective

    by Seyyed-Reza Sadat-Ebrahimi, Masoud Khalifezadeh, Shahrouz Ghaderi, Aysa Rezabakhsh

    Background: Ischemia/reperfusion injury (IRI) is a significant contributor to cardiac morbidity, while therapeutic options remain limited. According to previous evidence, C1q/TNF-related protein 9 (CTRP9), an adipokine with cardiometabolic regulatory properties, may serve as a potential modulator of myocardial injury. In this study, comprehensive bioinformatics analyses were primarily employed to identify hub genes and elucidate key therapeutic pathways associated with CTRP9 in the context of IRI. Methods: An interrelation analysis of hub genes was conducted to identify direct and indirect interactions. The resulting network and enrichment data were extracted from Cytoscape-GeneMANIA3.6.0, based on a genome-wide human interaction map, for further analysis and visualization. Results: Protein-protein interaction networks and functional enrichment analyses revealed that CTRP9 exerts cardioprotective effects primarily through the activation of adenosine monophosphate-activated protein kinase (AMPK) signaling, which leads to reduced cardiomyocyte apoptosis and enhanced angiogenesis. Notably, bioinformatics data suggested several downstream effectors, such as ucp1, gsk3b, and rps6kb1, as well as collagen-related genes (i.e., col4a2, col14a1, and col18a1), linked to the beneficial effects of CTRP9, considering it a promising therapeutic option related to IRI. Conclusion: These findings recommend several hub genes and pathways that may serve as novel therapeutic targets, highlighting the potential of CTRP9-based interventions for managing IRI-induced cardiac damage and improving clinical outcomes, particularly in cases of myocardial damage caused by IRI. Uncovering all possible underlying mechanisms could enhance our ability to better address the pathological sequelae following IRI.


  • Open Access

    Strict association between development of psychological conditions and hypertension incidence: A cross‐sectional study

    by Hossein Namdar, Fatemeh Jamshidi, Aysa Rezabakhsh, Davoud Ezzati, Raana Zakeri, Seyyed‐Reza Sadat‐Ebrahimi

    Background/Aims: Previous studies indicated a significant association between mental disorders and cardiovascular diseases, including heart failure (HF) and coronary artery disease (CAD) with comorbidity hypertension (HTN), and vice versa, leading to a challenge in the final decision. To resolve this issue, we aimed to exclude comorbidities and further assessed to better find any association between mental disorders and cardiovascular diseases (CVD).Methods: The cross‐sectional study involved 300 participants: 100 with HTN (without HF or CAD), 100 with HF (without HTN or CAD), 100 with CAD (without HTN or HF), and 100 healthy individuals as a control group. To evaluate depression, anxiety, and stress levels, the Depression, Anxiety, and Stress Scale – 21 (DASS‐21) was applied. For further analysis, the SPSS ver.20 was used.Results: The analysis showed that the score of depression, anxiety, and stress was higher in the HTN patients compared to the control (p < 0.001), CAD (p < 0.001), and HF (p < 0.001) groups, respectively. However, no significant differences were observed between the other study groups. Notably, patients with HF and CAD without concurrent HTN had similar psychological distress levels to healthy participants.Conclusion: The present study emphasized the higher prevalence of psychological distress in HTN patients and suggests a requirement for further research regarding the etiology involved in this association.


  • Open Access

    Myocardial and Vascular Involvement in Patients with Takayasu Arteritis: A Cardiovascular MRI Study

    by Simin Almasi, Sanaz Asadian, Leila Hosseini, Nahid Rezaeian, Shakiba Ghasemi Asl, Abdolmohammad Ranjbar, Seyyed-Reza Sadat-Ebrahimi, Behnaz Mahmoodieh, Alireza Salmanipour

    We aimed to explore the cardiovascular magnetic resonance (CMR) of Takayasu arteritis (TA) and its cardiovascular complications. CMR was conducted on 37 TA patients and 28 healthy individuals. We evaluated the CMR findings and adverse cardiovascular complications at the time of the CMR (ACCCMR). After 8 to 26 months, the major adverse cardiac and cerebrovascular events (MACCEs) were evaluated. The TA included 25 women (67.6%), aged 36 ± 16 years old, and 28 age- and sex-matched healthy controls. Left ventricular (LV) ejection fraction was significantly lower in the TA group than in the control group (51 ± 9% vs. 58 ± 1.7%; p < 0.001). Aortic mural edema was present in 34 patients (92%) and aortic mural hyperenhancement in 36 (97%). Left ventricular global longitudinal strain (LVGLS) was significantly lower in the TA group (median [interquartile range] = 13.70 [3.27] vs. 18.08 [1.35]; p < 0.001). ACCCMR was seen in 13 TA patients (35.1%), with the most common cardiac complication being myocarditis (16.2%). During a median follow-up of 18 months (8–26 months), nine patients developed MACCEs, of which the most common was cerebrovascular accident in five (13.5%). The LVGLS of the CMR had the strongest association with complications. Myocardial strain values, especially LVGLS, can reveal concurrent and future cardiovascular complications in TA patients.


  • Open Access

    Correction to: The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial

    by Naser Gharebaghi, Rahim Nejadrahim, Seyed Jalil Mousavi, Seyyed-Reza Sadat-Ebrahimi, Reza Hajizadeh

    An amendment to this paper has been published and can be accessed via the original article.


  • Open Access

    The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial

    by Naser Gharebaghi, Rahim Nejadrahim, Seyed Jalil Mousavi, Seyyed-Reza Sadat-Ebrahimi, Reza Hajizadeh

    Background: Coronavirus disease 2019 (COVID-19) has infected people in many countries worldwide. Discovering an effective treatment for this disease, particularly in severe cases, has become the subject of intense scientific investigation. Therefore, the objective of this study was to evaluate the efficacy of intravenous immunoglobulin (IVIg) in patients with severe COVID-19 infection.Methods: This study was conducted as a randomized placebo-controlled double-blind clinical trial. Fifty-nine patients with severe COVID-19 infection who did not respond to initial treatments were randomly assigned into two groups. One group received IVIg (human)—four vials daily for 3 days (in addition to initial treatment), while the other group received a placebo. Patients’ demographic, clinical, and select laboratory test results, as well as the occurrence of in-hospital mortality, were recorded.Results: Among total study subjects, 30 patients received IVIg and 29 patients received a placebo. Demographics, clinical characteristics, and laboratory tests were not statistically different (P > 0.05) between the two groups. The in-hospital mortality rate was significantly lower in the IVIg group compared to the control group (6 [20.0%] vs. 14 [48.3%], respectively;P = 0.025). Multivariate regression analysis demonstrated that administration of IVIg did indeed have a significant impact on mortality rate (aOR = 0.003 [95% CI: 0.001–0.815];P = 0.042).Conclusions: Our study demonstrated that the administration of IVIg in patients with severe COVID-19 infection who did not respond to initial treatment could improve their clinical outcome and significantly reduce mortality rate. Further multicenter studies with larger sample sizes are nonetheless required to confirm the appropriateness of this medication as a standard treatment.Trial registration: A study protocol was registered at the Iranian Registry of Clinical Trials (www.IRCT.ir), numberIRCT20200501047259N1. It was registered retrospectively on May 17th, 2020.


  • Open Access

    The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: A randomised placebo-controlled double-blind clinical trial

    by Naser Gharebaghi, Rahim Nejadrahim, Seyed Jalil Mousavi, Seyyed-Reza Sadat-Ebrahimi, Reza Hajizadeh

    Background: Coronavirus disease 2019 (COVID-19) has infected people in many countries worldwide. Discovering an effective treatment for this disease, particularly in severe cases, has become the subject of intense scientific investigation. Therefore, the objective of this study was to evaluate the efficacy of intravenous immunoglobulin (IVIg) in patients with severe COVID-19 infection.Methods: This study was conducted as a randomized placebo-controlled double-blind clinical trial. Fifty-nine patients with severe COVID-19 infection who did not respond to initial treatments were randomly assigned into two groups. One group received IVIg (human)—four vials daily for three days (in addition to initial treatment), while the other group received a placebo. Patients’ demographic, clinical, and select laboratory test results, as well as the occurrence of in-hospital mortality, were recorded.Results: Among total study subjects, 30 patients received IVIg and 29 patients received a placebo. Demographics, clinical characteristics, and laboratory tests were not statistically different (P > 0.05) between the two groups. The in-hospital mortality rate was significantly lower in the IVIg group compared to the control group (6 [20.0%] vs. 14 [48.3%], respectively; P = 0.022). Multivariate regression analysis demonstrated that administration of IVIg did indeed have a significant impact on mortality rate (aOR = 0.003 [95% CI: 0.001–0.815]; P = 0.042).Conclusions: Our study demonstrated that the administration of IVIg in patients with severe COVID-19 infection who did not respond to initial treatment could improve their clinical outcome and significantly reduce mortality rate. Further multicenter studies with larger sample sizes are nonetheless required to confirm the appropriateness of this medication as a standard treatment.Trial registration: A study protocol was registered at the Iranian Registry of Clinical Trials (www.IRCT.ir), number IRCT20200501047259N1. It was registered retrospectively on May 17th, 2020.

  • Open Access

    Hypertension But Not Heart Failure or Coronary Artery Disease is Associated with Mental Disorders

    by Hossein Namdar, Fatemeh Jamshidi, Davoud Ezzati, Raana Zakeri, Seyyed-Reza Sadat-Ebrahimi

    Background: Previous studies have emphasized the significant association between depression, anxiety, and stress and hypertension (HTN), heart failure (HF), and coronary artery disease (CAD). However, among included patients with HF or CAD in those studies, there were considerable proportions of patients with concomitant HTN and vice versa leading to some possible bias in final estimations. Therefore, we aimed to exclude those patients with concomitant diseases and reassess the association between these three prevalent cardiovascular diseases with three important psychological disorders. Methods: In this cross-sectional study, 300 patients were evaluated, including 100 with HTN (without a history or concomitant HF or CAD), 100 with HF (without HTN or CAD), and 100 with CAD (without HTN or HF). Moreover, 100 healthy volunteers were considered as the control group. Depression Anxiety Stress Scale 21 was used to measure the magnitude of depression, anxiety, and stress. Result: The average scores of 4.6, 9.1, 3.7, and 4.4 for depression, 3.9, 11.1, 4.1, and 3.6 for anxiety and 6.5, 13.6, 5.2, and 5.4 for stress were detected in control, HTN, CAD, and HF groups, respectively. The depression, anxiety, and stress scores of HTN group were significantly higher than the control (pConclusion: Our study demonstrated a significantly higher magnitude of psychological disorders in patients with HTN. However, their magnitude in patients with HF and CAD without concomitant HTN were similar to those in healthy participants.

  • Open Access

    Hypertension but Not Heart Failure or Coronary Artery Disease is Associated With Mental Disorders

    by Hossein Namdar, Fatemeh Jamshidi, Davoud Ezzati, Raana Zakeri, Seyyed-Reza Sadat-Ebrahimi

    Background Previous studies have emphasized the significant association between depression, anxiety, and stress and hypertension (HTN), heart failure (HF), and coronary artery disease (CAD). However, among included patients with HF or CAD in those studies, there were considerable proportions of patients with concomitant HTN and vice versa leading to some possible bias in final estimations. Therefore, we aimed to exclude those patients with concomitant diseases and reassess the association between these three prevalent cardiovascular diseases with three important psychological disorders. Methods In this cross-sectional study, 300 patients were evaluated, including 100 with HTN (without a history or concomitant HF or CAD), 100 with HF (without HTN or CAD), and 100 with CAD (without HTN or HF). Moreover, 100 healthy volunteers were considered as the control group. Depression Anxiety Stress Scale 21 was used to measure the magnitude of depression, anxiety, and stress. Result The average scores of 4.6, 9.1, 3.7, and 4.4 for depression, 3.9, 11.1, 4.1, and 3.6 for anxiety and 6.5, 13.6, 5.2, and 5.4 for stress were detected in control, HTN, CAD, and HF groups, respectively. The depression, anxiety, and stress scores of HTN group were significantly higher than the control (p < 0.05), CAD (p < 0.05) and HF (p < 0.05) groups; this is while these scores were not significantly different between other study groups (p > 0.05). Conclusion Our study demonstrated a significantly higher magnitude of psychological disorders in patients with HTN. However, their magnitude in patients with HF and CAD without concomitant HTN were similar to those in healthy participants.

  • Open Access

    A case of pheochromocytoma presenting with cardiac manifestation: case report

    by Akbar Molaei, Vahideh Abarzadeh-Bairami, Seyyed-Reza Sadat-Ebrahimi

    Background: Pheochromocytomas are rare tumors originating in chromaffin cells which predominantly are located in adrenal glands. Sustained or paroxysmal hypertension (HT) is the most frequent sign of pheochromocytoma. In some cases, it is associated with the classic triad including episodic headaches, sudoresis, and tachycardia; however, we present a case of pheochromocytoma with first presentation of cardiomyopathy. Case presentation: The authors describe a rare case of a pheochromocytoma which was first presented with cardiomyopathy in a 7-year-old patient. The patient was admitted with malaise, abdominal pain, polydipsia, and myalgia. Further evaluations revealed hyperglycemia, mild dehydration and sinus tachycardia but no HT. Echocardiography demonstrated some of the signs of cardiomyopathy which was incorrectly diagnosed as viral myocarditis. The patient was discharged with this diagnosis but he presented again with HT crisis a few months later. A diagnosis of pheochromocytoma was assigned after the evaluation of the HT secondary causes. The diagnosis was confirmed by metanephrine assay and the tumor was localized in the adrenal gland using the abdominal MRI. Conclusion: Pheochromocytoma can present itself with normotensive cardiomyopathy. Therefore, the possibility of pheochromocytoma should be considered in patients with cardiomyopathy especially in those with positive familial history.